Welcome to our dedicated page for A SPAC III Acqsn SEC filings (Ticker: ASPC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings of A SPAC III Acquisition Corp. (ASPC) provide detailed insight into its structure, governance, and progress toward completing an initial business combination. As a British Virgin Islands special purpose acquisition company listed on Nasdaq, ASPC discloses key events and shareholder actions through current reports, proxy statements, and other regulatory documents filed with the U.S. Securities and Exchange Commission.
Among the most significant filings is the definitive proxy statement on Schedule 14A, which explains the Charter Amendment Proposal to extend the company’s termination date for completing a business combination. This document outlines the rationale for the extension, the mechanics of the trust account, the redemption rights of public shareholders, and the potential consequences if no transaction is completed by the applicable deadline. It also describes the Agreement and Plan of Merger with Bioserica International Limited and the planned reincorporation and acquisition mergers involving A SPAC III’s wholly owned subsidiaries.
The Form 8-K filed on October 27, 2025 reports the results of the extraordinary general meeting at which shareholders approved the Charter Amendment Proposal. This filing details the vote counts, the number of shares tendered for redemption, and the effectiveness of the Amended and Restated Memorandum and Articles of Association, which extend the period to consummate a business combination to November 12, 2026.
On this SEC filings page, users can review ASPC’s 8-K current reports, proxy statements, and related exhibits to understand how the SPAC manages its combination period, handles shareholder redemptions, and structures its proposed merger with Bioserica. Stock Titan’s AI-powered tools can help summarize lengthy documents, highlight key terms such as termination dates and redemption conditions, and make it easier to interpret the implications of each filing for holders of ASPC shares and rights.
The preliminary proxy describes a proposed Charter Amendment to extend ASPC's combination deadline from November 12, 2025 to November 12, 2026 and related shareholder votes. It discloses a May 23, 2025 Merger Agreement to combine with Bioserica via a series of reincorporation and acquisition mergers, which the board unanimously approved and will be submitted to shareholders for separate approval. Public shareholders may redeem for a cash amount equal to the trust account balance (less up to $100,000 for dissolution expenses) divided by outstanding public shares; if the company winds up, rights to receive post-combination ordinary shares will expire worthless. The proxy notes the Sponsor does not currently intend to fund an extension, officers and insiders may not be reimbursed for excess out-of-pocket expenses if no combination occurs, founder/private placement shares remain locked until a business combination, and national security (CFIUS) and other regulatory risks may limit target availability.